

Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022 - A Hybrid Seminar Program Agenda

Pre-Program Activities	<p>Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min</p> <p>Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis and the transplant process – 45 min</p> <p>These presentations will be accessible through the conference app</p>
7:00am	<i>Registration and View Exhibits</i>
7:30 am	Opening Comments and Pre-Test
7:45 am	<p>Hepatitis C: Update on Diagnostics</p> <ul style="list-style-type: none"> • Short recap of key points from Pre-course lecture on viral hepatitis • Screening and diagnostic approaches of HCV <p>Hepatitis C: Update on Treatment</p> <ul style="list-style-type: none"> • AASLD/IDSA Guidelines and Updates • Simplified Guidance <p>Case Studies 1 –New Case relevant to diagnosis and treatment of high-risk HCV patient</p>
8:35am	<p>Hepatitis B: Epidemiology, Natural History and Testing</p> <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV
9:05 am	<p>Delta Hepatitis and Hepatitis E Update</p> <ul style="list-style-type: none"> • Worldwide perspective and promising research studies • Real world outcome studies on HDV and HEV
9:35 am	Product Theater #1 Break and View exhibits
10:15 am	<p>Anti-viral Therapies for HBV</p> <ul style="list-style-type: none"> • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Reactivation of HBV
10:45 am	<p>End Stage Liver Disease: Recap and Clinical Case</p> <ul style="list-style-type: none"> • A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and transplant <p>Case Study 2 – Cirrhosis and Encephalopathy</p>

11:15 am	Alcoholic Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Warning signs and intervention in alcoholic hepatitis
11:45 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery
12:15-12:40 pm	<i>Luncheon Presentation – Product Theater</i>
12:40-1:00pm	<i>Dessert and View Exhibits</i>
1:10 pm	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 3– Diagnosis and Treatment of Hepatocellular Carcinoma
1:40 pm	SARS-COV-2 in Liver Disease <ul style="list-style-type: none"> • Effect of COVID on the liver and in cirrhotic patients • COVID-19 challenges for liver transplant recipients
2:10pm	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
2:45 pm	<i>Break & View Exhibits</i>
3:00 pm	NAFLD and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Fatty Liver Disease • Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy • Drugs in clinical development for NASH
4:15 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:30 pm
Post-program activities	Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations - 45 minutes This presentation will be accessible through the conference app